ストックスクリーナーアプリを入手
0.95
0.00%
0.00
アフターアワーズ：
.95
前日終値:
$0.95
開ける：
$0.95
24時間の取引高:
27,101
Relative Volume:
0.33
時価総額：
$56.38M
収益：
-
当期純損益:
$-112.67M
株価収益率:
-0.4502
EPS:
-2.11
ネットキャッシュフロー:
$-79.26M
1週間 パフォーマンス:
-3.16%
1か月 パフォーマンス:
-4.31%
6か月 パフォーマンス:
-6.86%
1年 パフォーマンス:
+3.26%
1日の値動き範囲:
$0.935
$0.9631
1週間の範囲:
$0.92
$1.00
52週間の値動き範囲:
$0.69
$1.60
Kronos Bio Inc Stock (KRON) Company Profile
Kronos Bio Inc Stock (KRON) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-09-14 | 開始されました | Berenberg | Buy |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-06-24 | 開始されました | H.C. Wainwright | Buy |
| 2020-11-03 | 開始されました | Cowen | Outperform |
| 2020-11-03 | 開始されました | Goldman | Buy |
| 2020-11-03 | 開始されました | Jefferies | Buy |
| 2020-11-03 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Kronos Bio Inc (KRON) 最新ニュース
Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma - The Manila Times
Non-Hodgkin’s Lymphoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Non-Hodgkin Lymphoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Nio Inc ADR (NIO-N) QuotePress Release - The Globe and Mail
Phillips-Van Heusen Corp (PVH-N) QuotePress Release - The Globe and Mail
After Plunging -23.49% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON) - MSN
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors - The Manila Times
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium - GlobeNewswire
Taylor Morrison Home Corp (TMHC-N) QuotePress Release - The Globe and Mail
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors - The Manila Times
Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium - GlobeNewswire
Kronos Bio's (KRON) "Overweight" Rating Reaffirmed at Piper Sandler - MarketBeat
Kronos Bio nominates KAT inhibitor as development candidate for Sjögren’s disease - BioWorld Online
Piper Sandler maintains Overweight rating on Kronos Bio shares - Investing.com
Kronos Bio nominates KB-7898 for autoimmune disease treatment - Investing.com
Kronos Bio nominates KB-7898 for autoimmune disease treatment By Investing.com - Investing.com South Africa
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease - The Manila Times
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease - GlobeNewswire
Plexium Announces Appointment of Jorge F. DiMartino, M.D., Ph.D. as Chief Medical Officer - PR Newswire
Kronos Bio, Inc. (NASDAQ:KRON) Position Increased by Forefront Analytics LLC - Defense World
Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy - StockTitan
Kronos Bio to Present Data at ACR Convergence 2024 to - GlobeNewswire
Keros Therapeutics (NASDAQ:KROS) Shares Gap Up to $55.80 - Defense World
Avoro Capital Advisors LLC Reduces Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Integral Health Asset Management LLC Acquires 45,000 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
How the (KROS) price action is used to our Advantage - Stock Traders Daily
How does Keros Therapeutics Inc (KROS) change from a tortoise to a hare? - SETE News
Kronos Bio highlights istisociclib data at Ovarian Cancer Research Symposium - TipRanks
71,428 Shares in Korro Bio, Inc. (NASDAQ:KRRO) Acquired by Tri Locum Partners LP - MarketBeat
Kronos Bio Highlights Data at AACR Ovarian Cancer Research - GlobeNewswire
Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer - StockTitan
Keros Therapeutics (NASDAQ:KROS) Receives New Coverage from Analysts at Guggenheim - MarketBeat
Guggenheim starts Keros Therapeutics with 'buy' on lung disorder drug potential - XM
Guggenheim bullish on Keros Therapeutics stock driven by PAH treatment prospects - Investing.com Australia
Gogo Inc. (NASDAQ:GOGO) Shares Sold by Yarra Square Partners LP - Defense World
American Century Companies Inc. Has $13.63 Million Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Bought by Rhumbline Advisers - Defense World
Pharmacosmos after major acquisition: “The next six months are about integrating G1 well” - MedWatch
Understanding CRON stock ratios for better investment decisions - US Post News
DekaBank Deutsche Girozentrale Has $4.25 Million Holdings in Dollar Tree, Inc. (NASDAQ:DLTR) - Defense World
Kronos Bio, Inc. (NASDAQ:KRON) Short Interest Update - MarketBeat
ABIVAX Société Anonyme (NASDAQ:ABVX) Sees Large Growth in Short Interest - Defense World
After Plunging -5.53% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON) - Yahoo Finance
Kronos Bio Announces Participation in Medical and Investor Conferences in September - Marketscreener.com
The Psychology of Kronos Bio Inc Inc. (KRON) Price Performance: Understanding Market Sentiment - The InvestChronicle
Kronos Bio Inc (KRON) rating initates by Berenberg - Knox Daily
Kronos Bio Inc (KRON) 財務データ
収益
当期純利益
現金流量
EPS
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):